Itch

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, February 26, 2024
AAAAI, Injection, KIT, Research, Dermatology, Omalizumab, Eosinophilic esophagitis, B cell, Hypersensitivity, Quality of life, Work, Prurigo nodularis, Loss, DLQI, ILT4, Data, PD-1, Contingency, Inflammation, Cell, Myelocyte, Rockefeller University, Therapy, PN, Allergy, WCI, UAS7, Patient, Dermatology Life Quality Index, CSU, Survival, Congress, Disease, G&A, Itch, SRS, American Academy, Pharmaceutical industry

HAMPTON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • Celldex is currently planning two Phase 3 studies of barzolvolimab in CSU, which are expected to initiate this summer.
  • Celldex is currently planning for the initiation of a Phase 2 subcutaneous study in prurigo nodularis (PN) in early 2024.
  • The litigation settlement related loss had a ($0.26) impact on net loss per share for the twelve months ended December 31, 2023.
  • Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2023 are sufficient to meet estimated working capital requirements and fund current planned operations into 2026.

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

Retrieved on: 
Monday, February 26, 2024
SAN, Incidence, The Study, AAAAI, Caregiver, Angioedema, Histamine, Principal, ARS, FDA, Quality of life, Anaphylaxis, Body surface area, Data, Convention center, Skin, Safety, Joint task force, Allergy, Patient, Flare, Data analysis, CSU, Erythema, Pediatrics, Asthma, Adrenaline, Itch, American Academy, Pharmaceutical industry

Urticaria is a skin disorder that causes itchy hives and/or angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy.

Key Points: 
  • Urticaria is a skin disorder that causes itchy hives and/or angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy.
  • “Urticaria is not only a standalone type I allergy disease, but also represents the most frequent symptom observed during type I allergic reactions including anaphylaxis.
  • neffy may provide episodic symptomatic relief of these acute flares or exacerbations to improve the quality of life of urticaria patients.
  • This would follow the anticipated FDA approval of neffy for allergic reactions (Type I) including anaphylaxis in the second half of 2024.

Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

Retrieved on: 
Saturday, February 24, 2024
BTK, QPM, BID, AAAAI, Week, Omalizumab, TID, News, Prurigo nodularis, Asthma, Swelling, IgG4-related disease, Skin, Oral medicine, UAS7, Patient, CSU, Disease, Itch, LSM, ITT, American Academy, Pharmaceutical industry

Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines.

Key Points: 
  • Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines.
  • Significant reduction from baseline to week 12 in weekly urticaria activity score (UAS7) [LSM -17.95 vs -11.20, respectively; p=0.0116].
  • Significant reduction from baseline to week 12 in weekly hives severity score (HSS7) [LSM -8.31 vs -4.89; p
  • Rilzabrutinib is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.

Kenvue to Showcase 22 New Sets of Clinical Data at American Academy of Dermatology Association Meeting

Retrieved on: 
Thursday, March 7, 2024
Retail, Health, Home Goods, Other Health, Clinical Trials, General Health, Cream, Name, Skin, Woman, Efficacy, Psoriasis, Pigment, Education, Quality of life, Dermatology, Skin care, Risk, AAD, Itch, Dermatitis, Science, San Diego Convention Center, Inc., Theatre, American Academy, Cosmetics

Kenvue will also offer hands-on experiences in exhibit-floor Booth 2511, featuring products that are household names, including those from the Neutrogena®, Aveeno®, NeoStrata®, Lubriderm®, BAND-AID® Brand and Rogaine®1 portfolios.

Key Points: 
  • Kenvue will also offer hands-on experiences in exhibit-floor Booth 2511, featuring products that are household names, including those from the Neutrogena®, Aveeno®, NeoStrata®, Lubriderm®, BAND-AID® Brand and Rogaine®1 portfolios.
  • Additional data to be presented at AAD demonstrates the benefits of Kenvue’s formulations for skin hydration, sun protection and acne control.
  • Demonstrating the Clinical Effectiveness of Mineral Sunscreens in Protecting the Skin Against Ultraviolet A (UVA) Radiation-Induced Pigmentation; Shyr TC, et al.
  • On Friday and Saturday, Kenvue experts and key opinion leaders will also host R&D Theater presentations in the booth.

Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Development

Retrieved on: 
Monday, March 4, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Inhalation, Toxicology, Cough, Pain, Eye, Chronic cough, Venture round, Therapy, Patient, Knowledge, Disease, Itch, Pharmaceutical industry

Nocion Therapeutics, a clinical-stage biopharmaceutical company, today announced that it has raised $62 million in Series B funding.

Key Points: 
  • Nocion Therapeutics, a clinical-stage biopharmaceutical company, today announced that it has raised $62 million in Series B funding.
  • Proceeds from the financing will be used to evaluate the lead program, Taplucanium Dry Powder for Inhalation, in a Phase 2b study in Chronic Cough patients.
  • With this financing, Nocion has raised $122 million since the company was founded in 2018.
  • “We are grateful to our new and existing investors for their commitment to our lead program in this challenging disease,” said Dr. Richard Batycky, Chief Executive Officer of Nocion.

Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting

Retrieved on: 
Friday, March 1, 2024
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Cream, LTS, Pros, Therapy, Incidence, Week, Psoriasis, Dermatology, Headache, Political moderate, Atopic dermatitis, Pain, Validation, Swelling, Itch, DLQI, Skin, Irritation, Folliculitis, Accepted, Common, QD, Stinger, Safety, Abstract, Patient, Rash, San Diego Convention Center, Nose, American Academy, Vaccine

VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of atopic dermatitis (AD).

Key Points: 
  • VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of atopic dermatitis (AD).
  • VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. and is the same strength and formulation being studied in the ADORING Phase 3 development program for AD.
  • The following posters will be viewable onsite at the San Diego Convention Center.
  • Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

New Two-Year Results Show Sustained Improvement in Chronic Rhinitis Symptoms Following a Single Procedure with Aerin Medical’s RhinAer®

Retrieved on: 
Thursday, February 29, 2024
Health, Medical Devices, Health Technology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Ear, Multimedia, Randomized controlled trial, Sneeze, Inflammation, Nose, Physician, Quality of life, Itch, Congestion, ENT, Patient, Otorhinolaryngology, Allergy, Cough, Pharmaceutical industry

These results demonstrate the durable treatment effect of RhinAer® for treating chronic rhinitis, showing a significant improvement in symptoms through two years.

Key Points: 
  • These results demonstrate the durable treatment effect of RhinAer® for treating chronic rhinitis, showing a significant improvement in symptoms through two years.
  • These findings build on the previously published results of two separate studies that also demonstrated significant, sustained improvement with RhinAer treatment.1,2
    This press release features multimedia.
  • More than 87% of patients responded to treatment and patients showed sustained improvement in chronic rhinitis symptoms at two years.
  • Chronic rhinitis, when symptoms last more than four consecutive weeks, can be challenging to treat and may significantly lower a person’s quality of life.

Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting

Retrieved on: 
Wednesday, February 28, 2024
Research, Clinical Trials, Biotechnology, Managed Care, Health, Cosmetics, Pharmaceutical, Retail, Science, Acne, Nemolizumab, Pacific Ocean, Atopic dermatitis, Prurigo nodularis, Hyperhidrosis, Dermatology, Skin, Consultant, AAD, Marriott Marquis, Safety, Patient, Itch, START, American Academy, Medical device

Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.

Key Points: 
  • Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.
  • “Our vast presence at AAD combines new data, novel educational activities and patient perspectives, demonstrating how we are putting our commitment to addressing the needs of the dermatology community into action.
  • The event is taking place on Saturday, March 9, in the Pacific Ballroom 21-26, Marriott Marquis San Diego Marina, from 7:00 to 9:00 PM PST.
  • *All presenters are paid consultants or employees of Galderma.

First Day Introduces Women's Good Gut - The World's 1st Women's Gummy 3-in-1 Pre+ Post+ Probiotic!

Retrieved on: 
Thursday, March 7, 2024
Skin, Probiotic, Woman, Absorption, Digestion, Bloating, Growth, Overalls, Postbiotic, First, Dentistry, Vagina, Defecation, Constipation, Immunity, Nutrient, Movement, Itch, Nutritional science, Ageing, Birth control

AUSTIN, Texas, March 7, 2024 /PRNewswire-PRWeb/ -- First Day, the brand trusted for its innovative line of multivitamins for kids, teens, women, and men, announced today the launch of a groundbreaking product: Women's Good Gut. The world's first tri-biotic designed specifically to address digestive, immune, and vaginal health concerns in women aged 18 and above. A 30-day supply of kiwi-flavored gummies, this product aims to empower women to take control of their gut health and overall well-being. Spearheaded by CEO and Founder, Alice Li, this revolutionary supplement marks a significant milestone in women's wellness.

Key Points: 
  • A 30-day supply of kiwi-flavored gummies, this product aims to empower women to take control of their gut health and overall well-being.
  • A 30-day supply of kiwi-flavored gummies, this product aims to empower women to take control of their gut health and overall well-being.
  • Women's Good Gut is now available for purchase on the First Day website ( www.firstday.com ), offering women a holistic approach to gut health and well-being.
  • Join the movement towards optimal wellness with Women's Good Gut from First Day.

Sun Pharma Launches WINLEVI® (clascoterone) Cream 1% Connected TV (CTV) Ad Campaign with Dr. Sandra Lee (a.k.a. "Dr. Pimple Popper")

Retrieved on: 
Wednesday, March 6, 2024
Amazon Prime Video, Social media, Gettin' Ready, Netflix, Marketing, Adolescence, Acne, Smart TV, Connected, Toxicity, Family Dinner, Inflammation, FDA, Gland, Dermatology, Parent, Skin, Itch, Edema, Potassium, Hulu, Stinger, Irritation, Hyperkalemia, Apple TV, CTV, Clascoterone, Patient, Sebaceous gland, Game Night, Diagnosis, Sun Pharma, HPA, Research

WINLEVI is the first and only FDA-approved topical acne treatment available in the U.S. that targets sebum production in the skin.

Key Points: 
  • WINLEVI is the first and only FDA-approved topical acne treatment available in the U.S. that targets sebum production in the skin.
  • "We are thrilled to continue our collaboration with Dr. Sandra Lee, whose persona as 'Dr.
  • Pimple Popper' fits well with our use of humorous and relatable content to connect with teens.
  • Additionally, edema, stinging, and burning occurred in >3% of patients and were reported in a similar percentage of subjects treated with vehicle.